Leave message
Can’t find what you’re looking for?
Fill out this form to inquire about our custom protein services!
Inquire about our Custom Services >>
ID | Components | Size |
EP129-C01 | High-bind Plate | 1 plate |
EP129-C02 | Human IL-7 R alpha & TSLP R | 25 μg |
EP129-C03 | Anti- TSLP Neutralizing Antibody | 20 μg |
EP129-C04 | Human TSLP-Biotin | 10 μg |
EP129-C05 | Streptavidin-HRP | 10 μg |
EP129-C06 | Coating Buffer | 12 mL |
EP129-C07 | 10xWashing Buffer | 50 mL |
EP129-C08 | Blocking Buffer | 50 mL |
EP129-C09 | Substrate Solution | 12 mL |
EP129-C10 | Stop Solution | 7 mL |
2. Find the expiration date on the outside packaging and do not use reagents past their expiration date.
3. The opened kit should be stored per components table. The shelf life is 30 days from the date of opening.
INHIBITION OF TSLP [BIOTINYLATED]: IL-7 R ALPHA & TSLP R BINDING BY ANTI-TSLP NEUTRALIZING ANTIBODY
Serial dilutions of Anti-TSLP Neutralizing antibody (Catalog # EP129-C03) (1:1 serial dilution, from 8 μg/mL to 0.0156 μg/mL (55.317-0.108 nM)) was added into IL-7 R alpha & TSLP R: TSLP-Biotin binding reactions. The assay was performed according to the above-described protocol. Background was subtracted from data points prior to log transformation and curve fitting (QC tested).
INHIBITION OF TSLP [BIOTINYLATED]: IL-7 R ALPHA & TSLP R BINDING BY ANTI- TSLP & IL-13 BISPECIFIC ANTIBODY
Serial dilutions of anti TSLP & IL-13 bispecific antibody (1:1 serial dilution, from 8 μg/mL to 0.0156 μg/mL (55.317-0.108 nM)) was added into IL-7 R alpha & TSLP R: TSLP-Biotin binding reactions. The assay was performed according to the above-described protocol. Background was subtracted from data points prior to log transformation and curve fitting (Routinely tested).
Explore our catalog of therapeutic antibody solutions to find the right products for you! We are dedicated to delivering solutions designed to help you drive innovation and push the boundaries of what therapeutic antibodies can be.
We offer a wide range of cell and gene therapy solutions starting from discovery to the clinic. Explore our wide range of proteins, antibodies, kits, and other assays to accelerate the development of your cell and gene therapy.
Organoid Toolbox is a collection of organoid solutions including ready-to-use organoids, organoid differentiation kits, and a variety of services to accelerate the progress of your drug development project.
ACROBiosystems developed a series of GMP grade cytokines under the GMP grade quality management system. Those products are all suitable for T/NK cell generation, activation, and proliferation in cell therapy research.
50+ targets designed for CAR detection, including PE/FITC/biotin labeled proteins. The key reagents for CD19 and BCMA were FDA DMF filed which can support your IND, NDA and BLA process.
GMP grade cytokines, reagents for cell activation, gene edition, DNA/RNA removal, etc. Particularly focus on product design, quality control and solution-based support to link each phase of your cell and gene therapy journey.
Full length multi-pass TPs with stabilized structure and high bioactivity for immunization, antibody screening, cell based assay and CAR detection, including hot CD20, Claudin 18.2, CD133, GPRC5D,CCR8, CCR5, etc.
A series of immune checkpoints including classic co-inhibitory and co-stimulatory receptors. The comprehensive catalog contains 100+ targets with various species and tags, and the high-quality proteins are in good batch-to-batch consistency.
To meet the needs of ADCs development, ACROBiosystems can provide: A variety of high-quality target proteins; MMPs/Cathepsin/uPA for cleavable linker; Anti-payload antibodies & anti-idiotypic antibodies for immunogenicity and PK analysis; SPR/BLI analytical and ADA development service.
Comprehensive collection of Fc receptor proteins, including their common variants, which can help expedite your antibody development.
Comprehensive cytokine targets including interleukins, growth factors, chemokines, TNFs, etc. are expressed by HEK293 to ensure their natural structure. Their high purity is verified by SDS-PAGE/HPLC/SEC-MALS and high bioactivity is verified by ELISA/SPR/BLI.
Aneuro provides comprehensive tools for neuroscience research, including neuroscience proteins, pre-formed fibrils (PFFs), neural antibodies, neural factors, and more—aiming to accelerate disease modeling, drug screening, and neural mechanism studies.
English Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|
English Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
Interleukin-7 (Revimmune SAS) | rhIL-7; CYT-107; CYT-99-007 | Phase 2 Clinical | Revimmune Inc | Prostatic Neoplasms, Castration-Resistant; Neuroectodermal Tumors, Primitive, Peripheral; Catheter-Related Infections; Rhabdomyosarcoma, Alveolar; T-Lymphocytopenia, Idiopathic CD4-Positive; Leukemia, Myeloid, Acute; Metastatic breast cancer; Hepatitis C; Ureteral Neoplasms; Urologic Neoplasms; Lymphopenia; Sarcoma; Neuroblastoma; Prostatic Neoplasms; Urethral Neoplasms; Multiple Myeloma; HIV Infections; Urinary Bladder Neoplasms; Myeloproliferative Disorders; Sepsis; Carcinoma, Transitional Cell; Coronavirus Disease 2019 (COVID-19); Mycobacterium Infections, Nontuberculous; Myelodysplastic Syndromes; Rhabdomyosarcoma, Embryonal; Hepatitis B, Chronic; Carcinoma, Renal Cell; Leukemia, Myelogenous, Chronic; Kidney Neoplasms; Skin Melanoma; Shock, Septic | Details |
Lusvertikimab | S-95011; Effi-7; OSE-217; OSE-127 | Phase 2 Clinical | Effimune | Sjogren's Syndrome; Colitis, Ulcerative | Details |
Efineptakin alfa | TJ-107; GX-I7; NT-I7 | Phase 2 Clinical | Genexine Inc | Urinary Bladder Neoplasms; Sarcoma, Kaposi; Melanoma; Carcinoma, Non-Small-Cell Lung; Laryngeal Neoplasms; Leukoencephalopathy, Progressive Multifocal; Carcinoma, Squamous Cell; Glioma; Oropharyngeal Neoplasms; Gliosarcoma; Lymphopenia; Astrocytoma; Colorectal Neoplasms; Plasmablastic Lymphoma; Breast Neoplasms; Prostatic Neoplasms, Castration-Resistant; Solid tumours; Pancreatic Neoplasms; Small Cell Lung Carcinoma; Papillomavirus Infections; Hypopharyngeal Neoplasms; Lymphoma, Large B-Cell, Diffuse; Glioblastoma; Triple Negative Breast Neoplasms; Coronavirus Disease 2019 (COVID-19); Carcinoma, Merkel Cell; Esophageal Neoplasms; Squamous Cell Carcinoma of Head and Neck; HIV Infections; Ovarian Neoplasms; Lymphoma, B-Cell | Details |
ASP-9801 | ASP-9801 | Phase 1 Clinical | Astellas Pharma Inc | Solid tumours; Neoplasms; Neoplasm Metastasis | Details |
PF-06342674 | RN-168; PF-6342674; PF-06342674; ZB-168 | Phase 1 Clinical | Pfizer Inc | Diabetes Mellitus, Type 1; Multiple Sclerosis | Details |
Loco-regional B7H3 IL-7Ra CAR T Cell therapy(Chulalongkorn University) | Phase 1 Clinical | Chulalongkorn University, King Chulalongkorn Memorial Hospital | Solid tumours; Neoplasms; Brain Neoplasms; Diffuse Intrinsic Pontine Glioma | Details | |
MDK-703 | MDK-703 | Phase 1 Clinical | Medikine Inc | Solid tumours | Details |
This web search service is supported by Google Inc.